Cite
HARVARD Citation
Batt, K. et al. (2022). A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab. Current medical research and opinion. pp. 1685-1693. [Online].